Search results for: “MNK”

  • Mallinckrodt PLC Valuation – July 2018 $MNK

    Mallinckrodt PLC Valuation – July 2018 $MNK

    Mallinckrodt PLC does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the small size, insufficient earnings stability over the last ten years, and the poor dividend history.

  • Mallinckrodt PLC Valuation – August 2016 $MNK

    Mallinckrodt PLC Valuation – August 2016 $MNK

    Mallinckrodt PLC does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings stability over the last ten years, the poor dividend history, and the high PEmg ratio.

  • Mallinckrodt PLC Analysis – Initial Coverage $MNK

    Mallinckrodt PLC Analysis – Initial Coverage $MNK

    Mallinckrodt PLC does not qualify for either the Defensive Investor and the Enterprising Investor. The Defensive Investor is concerned with the short history as a stand alone company, lack of dividends, and the high PEmg and PB ratios.

  • Zoetis Inc Valuation – January 2019 $ZTS

    Zoetis Inc Valuation – January 2019 $ZTS

    Zoetis Inc is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the insufficient earnings stability over the last ten years, and the poor dividend history, and the high PEmg and PB ratios.

  • Gilead Sciences Inc Valuation – January 2019 $GILD

    Gilead Sciences Inc Valuation – January 2019 $GILD

    Gilead Sciences, Inc. qualifies for both the Defensive Investor and the Enterprising Investor. The Defensive Investor is only initially concerned with the poor dividend history.

  • Pfizer Inc Valuation – November 2018 $PFE

    Pfizer Inc Valuation – November 2018 $PFE

    Pfizer Inc. does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, high PEmg and PB ratios.

  • Nektar Therapeutics Valuation – November 2018 $NKTR

    Nektar Therapeutics Valuation – November 2018 $NKTR

    Nektar Therapeutics does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the insufficient earnings stability or growth over the last ten years, and the poor dividend history, and the high PEmg and PB ratios.

  • Merck & Co Inc Valuation – November 2018 $MRK

    Merck & Co Inc Valuation – November 2018 $MRK

    Merck & Co., Inc. does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings growth over the last ten years, and the high PEmg and PB ratios.

  • Ligand Pharmaceuticals Inc Valuation – September 2018 $LGND

    Ligand Pharmaceuticals Inc Valuation – September 2018 $LGND

    Ligand Pharmaceuticals Inc. does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the insufficient earnings stability or growth over the last ten years, and the poor dividend history, and the high PEmg and PB ratios.

  • Supernus Pharmaceuticals Inc Valuation – August 2018 $SUPN

    Supernus Pharmaceuticals Inc Valuation – August 2018 $SUPN

    Supernus Pharmaceuticals Inc does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the insufficient earnings stability or growth over the last ten years, and the poor dividend history, and the high PEmg and PB ratios.